Objective To understand the situation of medication treatment in out-patients with hypertension.Method 1 210 out-patients with hypertension were investigated by ourselves-made questionnaire on their medication treatment at home.Results In all of the patients,there was only 30.74% of them persisting in taking regular medication.The control rate on blood pressure was 70.96% in patients with regular taking medication and 28.99% in patients with irregular taking medication.The rates of regular taking medication in goverment staff,teachers and retirees were higher.The compliance with medication treatment was increased with the age.There was 79.83% of patients discontinued to take medication after 3-6 months of medication treatment.Conclusion The situation of medication treatment in outpatients is less optimistic.We should strengthen the blood pressure controll in outpatients of the young aged,workers and peasants.

Objective:To evaluate the safety and efficacy of enteromorpha prolifera enzymatic hydrolysate in alleviating scalp sensitive symptoms.Methods:The inhibitory effects of different concentrations of enteromorpha prolifera hydrolysate on tumor necrosis factor (TNF)-α, interleukin (IL)-1α, IL-6, and other inflammatory factors were observed through in vitro experiments. Subsequently, the abilities to scavenge [2, 2＇-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid)] (ABTS) and to promote proliferation of mouse fibroblasts were evaluated. A prospective study was conducted on 20 patients with scalp sensitivity at Qingdao Hiser Hospital Affiliated to Qingdao University from April 2023 to October 2023. The patients included 2 males and 18 females with an average age of (34.9±10.3) years. They were treated with a scalp essence containing 10% enteromorpha enzymatic hydrolysate for consecutive 28 days. Changes in scalp cuticle water content, transepidermal water loss (TEWL), and oil content were measured before and after 14 and 28 days of treatment. Expert interviewers assessed the skin irritation test to elucidate any undesirable side effects.Results:The results of in vitro experiments demonstrated that enteromorpha protophora enzymatic hydrolysate at different concentrations exhibited inhibitory effects on the expression of IL-1α, IL-6, and TNF-α, while it also displayed a dose-dependent ability to scavenge ABTS free radicals. Furthermore, it effectively promoted the proliferation of mouse fibroblasts, resulting in a significant increase of 43.22% in fibroblast viability when the concentration of enteromorpha protophora enzymatic hydrolysate was 0.10%. The outcomes from clinical trials revealed that after using a scalp essence containing enteromorpha protophora enzymatic hydrolysate for 14 and 28 days, there were significant improvements observed in terms of increased water content in the scalp epidermis, along with decreased oil content and TEWL value (all P< 0.001). Moreover, remarkable effective rates were achieved for treating various scalp conditions including redness (80.0%, 16/20), dandruff (80.0%, 16/20), itching (85.0%, 17/20), stinging sensation (90.0%, 18/20), and tightness (80.0%, 16/20) after using the scalp essence for 28 days. Adverse effects on the skin were not observed in any subject during the test period. Conclusions:The enzymatic hydrolysate of enteromorpha demonstrates both safety and efficacy in alleviating symptoms associated with scalp sensitivity.